Xcout Intel
Forty Seven
Forty Seven, Inc. is a clinical-stage immuno-oncology company headquartered in Menlo Park, California, that develops therapies targeting cancer immune evasion pathways.
Subscribe to see Forty Seven’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Forty Seven at a glance
Forty Seven is a healthcare company headquartered in United States. It has raised at least $184.1M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $75M in October 2017. Xcout tracks 17 named people at Forty Seven, including Daniel O'Day (Chairman and Chief Executive Officer, Gilead Sciences).
Forty Seven leadership
- Daniel O'DayChairman and Chief Executive Officer, Gilead Sciences
- Andrew DickinsonChief Financial Officer
- Dietmar BergerChief Medical Officer
- Johanna MercierChief Commercial & Corporate Affairs Officer
- Cindy PerettieExecutive Vice President, Kite
- Flavius MartinExecutive Vice President, Research
11 more named people on record for Forty Seven, with roles, board committees and tenure — see the full roster →
Forty Seven funding rounds
At least $184.1M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $75M | 1 named | |
| Series B | $75M | 1 named | |
| SEC Form D filing | $34.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Forty Seven competitors
A few of Forty Seven's closest competitors — see the full list of competitors and alternatives →
Gritstone bio, Inc. is a clinical-stage biotechnology company headquartered in Emeryville, California. The firm engages in developing next-generation cancer immunotherapies and vaccines to fight various forms of cancer and infectious diseases.
Eigen Therapeutics is a biotechnology company headquartered in Redwood City, California, focused on developing 'priming' therapies that make cancer easier to find and eliminate.
Nuvig Therapeutics, Inc. is a company headquartered in Palo Alto, California, dedicated to developing novel immune and therapeutic treatments for chronic autoimmune diseases.
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company that develops novel immunotherapies and macrophage-targeting treatments for cancer patients. Its lead candidate, bexmarilimab, is an anti-Clever-1 antibody being evaluated in clinical trials for hematological cancers and solid tumors to improve the efficacy of standard cancer treatments.
Get Forty Seven's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Forty Seven in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access